Area of research
Oncology · Immunology
Research interest
Research interests include HER2/EGFR in Cancer Research, Immunotherapy and Immune Responses, Cancer Treatment and Pharmacology, and Cancer Immunotherapy and Biomarkers.
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study
European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment